Is current risk assessment of non-genotoxic carcinogens protective?

References

• Alexander DJ, Collins CJ, Coombs DW, Gilkison IS, Hardy CJ, Healey G, Karantabias G, Johnson N, Karlsson A, Kilgour JD, et al. 2008. Association of Inhalation Toxicologists (AIT) working party recommendation for standard delivered dose calculation and expression in non-clinical aerosol inhalation toxicology studies with pharmaceuticals. Inhal Toxicol. 20:1179–1189.
   PubMed Web of Science ®Google Scholar
• Allen BC, Kavlock RJ, Kimmel CA, Faustman EM. 1994. Dose-response assessment for developmental toxicity. II. Comparison of generic benchmark dose estimates with no observed adverse effect levels. Fundam Appl Toxicol. 23:487–495.
   PubMedGoogle Scholar
• Barlow S, Renwick AG, Kleiner J, Bridges JW, Busk L, Dybing E, Edler L, Eisenbrand G, Fink-Gremmels J, Knaap A, et al. 2006. Risk assessment of substances that are both genotoxic and carcinogenic report of an International Conference organized by EFSA and WHO with support of ILSI Europe. Food Chem Toxicol. 44:1636–1650.
   PubMed Web of Science ®Google Scholar
• Bemis JC, Wills JW, Bryce SM, Torous DK, Dertinger SD, Slob W. 2016. Comparison of in vitro and in vivo clastogenic potency based on benchmark dose analysis of flow cytometric micronucleus data. Mutagenesis. 31:277–285.
   PubMed Web of Science ®Google Scholar
• Benigni R, Bossa C, Tcheremenskaia O. 2013. Nongenotoxic carcinogenicity of chemicals: mechanisms of action and early recognition through a new set of structural alerts. Chem Rev. 113:2940–2957.
   PubMed Web of Science ®Google Scholar
• Billington R, Lewis RW, Mehta JM, Dewhurst I. 2010. The mouse carcinogenicity study is no longer a scientifically justifiable core data requirement for the safety assessment of pesticides. Crit Rev Toxicol. 40:35–49.
   PubMed Web of Science ®Google Scholar
• Burden N, Mahony C, Muller BP, Terry C, Westmoreland C, Kimber I. 2015. Aligning the 3Rs with new paradigms in the safety assessment of chemicals. Toxicology. 330:62–66.
   PubMed Web of Science ®Google Scholar
• Butterworth BE, Bogdanffy MS. 1999. A comprehensive approach for integration of toxicity and cancer risk assessments. Regul Toxicol Pharmacol. 29:23–36.
   PubMed Web of Science ®Google Scholar
• Chiu WA, Slob W. 2015. A unified probabilistic framework for dose-response assessment of human health effects. Environ Health Perspect. 123:1241–1254.
   PubMed Web of Science ®Google Scholar
• Cohen SM. 1998. Cell proliferation and carcinogenesis. Drug Metab Rev. 30:339–357.
   PubMed Web of Science ®Google Scholar
• Cohen SM, Ellwein LB. 1990. Cell proliferation in carcinogenesis. Science. 249:1007–1011.
   PubMed Web of Science ®Google Scholar
• Cohen SM, Ellwein LB. 1991. Genetic errors, cell proliferation, and carcinogenesis. Cancer Res. 51:6493–6505.
   PubMed Web of Science ®Google Scholar
• Cohen SM, Klaunig J, Meek ME, Hill RN, Pastoor T, Lehman-McKeeman L, Bucher J, Longfellow DG, Seed J, Dellarco V, et al. 2004. Evaluating the human relevance of chemically induced animal tumors. Toxicol Sci. 78:181–186.
   PubMed Web of Science ®Google Scholar
• Committee on Human and Environmental Exposure Science in the 21st Century, Board on Environmental Studies and Toxicology, Division on Earth and Life Studies, National Research Council. 2012. Exposure science in the 21st century: a vision and a strategy. Washington (DC): National Academies Press (US).
   Google Scholar
• EC. 2001. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the community code relating to medicinal products for human use. OJ L. 311:67–128.
   Google Scholar
• EC. 2008. Council Regulation (EC) No 440/2008 of 30 May 2008 laying down test methods pursuant to Regulation (EC) No 1907/2006 of the European Parliament and of the Council on the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH). OJ L 142:1.
   Google Scholar
• EC. 2009. Regulation No 1107/2009 of the European Parliament and of the Council of 21 October 2009 concerning the placing of plant protection products on the market and repealing Council Directives 79/117/EEC and 91/414/EEC. OJ L 309 of 24112009: 1–50.
   Google Scholar
• EC. 2013. Commission Regulation (EU) No 284/2013 of 1 March 2013 setting out the data requirements for plant protection products, in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council concerning the placing of plant protection products on the market. OJ L. 93:85–152.
   Google Scholar
• ECHA. 2012. Guidance on information requirements and chemical safety assessment Chapter R.8: Characterisation of dose [concentration]-response for human health. Helsinki, Finland: ECHA.
   Google Scholar
• EFSA. 2005. Opinion of the Scientific Committee on a request from EFSA related to a harmonised approach for risk assessment of substances which are both genotoxic and carcinogenic. EFSA J. 282:1–31.
   Google Scholar
• EFSA. 2009. Guidance of the Scientific Committe on a request from EFSA on the use of the benchmark dose approach in risk assessment. EFSA J. 1150:1–72.
   Google Scholar
• EFSA. 2012. EFSA opinion – Guidance on selected default values to be used by the EFSA Scientific Committee, Scientific Panels and Units in the absence of actual measured. EFSA J. 10:2579.
   Google Scholar
• Embry MR, Bachman AN, Bell DR, Boobis AR, Cohen SM, Dellarco M, Dewhurst IC, Doerrer NG, Hines RN, Moretto A, et al. 2014. Risk assessment in the 21st century: roadmap and matrix. Crit Rev Toxicol. 44 Suppl 3:6–16.
   PubMed Web of Science ®Google Scholar
• European Food Safety Authority. 2005. Opinion of the Scientific Committee on a request from EFSA related to a harmonised approach for risk assessment of substances which are both genotoxic and carcinogenic. EFSA J. 3:282.
   Google Scholar
• Fowles JR, Alexeeff GV, Dodge D. 1999. The use of benchmark dose methodology with acute inhalation lethality data. Regul Toxicol Pharmacol. 29:262–278.
   PubMed Web of Science ®Google Scholar
• Greenfield RE, Ellwein LB, Cohen SM. 1984. A general probabilistic model of carcinogenesis: analysis of experimental urinary bladder cancer. Carcinogenesis. 5:437–445.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. Cell. 100:57–70.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell. 144:646–674.
   PubMed Web of Science ®Google Scholar
• Henderson BE, Ross R, Bernstein L. 1988. Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res. 48:246–253.
   PubMed Web of Science ®Google Scholar
• Hernandez LG, van Steeg H, Luijten M, van Benthem J. 2009. Mechanisms of non-genotoxic carcinogens and importance of a weight of evidence approach. Mutat Res. 682:94–109.
   PubMed Web of Science ®Google Scholar
• Holsapple MP, Pitot HC, Cohen SM, Boobis AR, Klaunig JE, Pastoor T, Dellarco VL, Dragan YP. 2006. Mode of action in relevance of rodent liver tumors to human cancer risk. Toxicol Sci. 89:51–56.
   PubMed Web of Science ®Google Scholar
• IARC. 2016. Agents classified by the IARC monographs, volumes 1–115. Lyon, France: IARC; [accessed 2017 June 6]. http://monographs.iarc.fr/ENG/Classification/.
   Google Scholar
• ICH. 1995. Guideline S1A: Need for carcinogenicity studies of pharmaceuticals. Geneva: ICH.
   Google Scholar
• ICH. 1997. Guideline S1B: Testing for carcinogenicity of pharmaceuticals. Geneva: ICH.
   Google Scholar
• ICH. 2008. Guideline S1C (R2): Dose Selection for Carcinogenicity Studies of Pharmaceuticals. Geneva: ICH.
   Google Scholar
• Jacobs MN, Colacci A, Louekari K, Luijten M, Hakkert BC, Paparella M, Vasseur P. 2016. International regulatory needs for development of an IATA for non-genotoxic carcinogenic chemical substances. ALTEX. 33:359–392.
   PubMedGoogle Scholar
• Kavlock RJ, Allen BC, Faustman EM, Kimmel CA. 1995. Dose-response assessments for developmental toxicity. IV. Benchmark doses for fetal weight changes. Fundam Appl Toxicol. 26:211–222.
   PubMedGoogle Scholar
• Lai DY, Woo YT. 2003. Chapter 2: mechanisms of action of chemical carcinogens and their role in structure–activity relationships (SAR) analysis and risk assessment. In: Raton B, editor. Quantitative structure-activity relationship (QSAR) models of mutagens and carcinogens. Boca Raton (FL): CRC Press; p. 41–80.
   Google Scholar
• Meek ME, Bucher JR, Cohen SM, Dellarco V, Hill RN, Lehman-McKeeman LD, Longfellow DG, Pastoor T, Seed J, Patton DE. 2003. A framework for human relevance analysis of information on carcinogenic modes of action. Crit Rev Toxicol. 33:591–653.
   PubMed Web of Science ®Google Scholar
• Melnick RL, Kohn MC, Portier CJ. 1996. Implications for risk assessment of suggested nongenotoxic mechanisms of chemical carcinogenesis. Environ Health Perspect. 104 (Suppl 1):123–134.
   PubMed Web of Science ®Google Scholar
• National Academies of Sciences, Engineering, and Medicine, Division on Earth and Life Studies, Board on Environmental Studies and Toxicology, Committee on Incorporating 21st Century Science into Risk-Based Evaluations. 2017. Using 21st Century Science to Improve Risk-Related Evaluations. Washington (DC): National Academies Press (US).
   Google Scholar
• NRC. 2007. Toxicity testing in the 21st century: a vision and a strategy. Washington (DC): The National Academies Press.
   Google Scholar
• Pastoor TP, Bachman AN, Bell DR, Cohen SM, Dellarco M, Dewhurst IC, Doe JE, Doerrer NG, Embry MR, Hines RN, et al. 2014. A 21st century roadmap for human health risk assessment. Crit Rev Toxicol. 44(Suppl 3):1–5.
   PubMed Web of Science ®Google Scholar
• Preston-Martin S, Pike MC, Ross RK, Jones PA, Henderson BE. 1990. Increased cell division as a cause of human cancer. Cancer Res. 50:7415–7421.
   PubMed Web of Science ®Google Scholar
• Purchase IF. 1994. Current knowledge of mechanisms of carcinogenicity: genotoxins versus non-genotoxins. Hum Exp Toxicol. 13:17–28.
   PubMed Web of Science ®Google Scholar
• Schaap MM, Wackers PF, Zwart EP, Huijskens I, Jonker MJ, Hendriks G, Breit TM, van Steeg H, van de Water B, Luijten M. 2015. A novel toxicogenomics-based approach to categorize (non-)genotoxic carcinogens. Arch Toxicol. 89:2413–2427.
   PubMed Web of Science ®Google Scholar
• Silva Lima B, Van der Laan JW. 2000. Mechanisms of nongenotoxic carcinogenesis and assessment of the human hazard. Regul Toxicol Pharmacol. 32:135–143.
   PubMed Web of Science ®Google Scholar
• Simon TW, Simons SS Jr, Preston RJ, Boobis AR, Cohen SM, Doerrer NG, Fenner-Crisp PA, McMullin TS, McQueen CA, Rowlands JC. 2014. The use of mode of action information in risk assessment: quantitative key events/dose-response framework for modeling the dose-response for key events. Crit Rev Toxicol. 44(Suppl 3):17–43.
   PubMed Web of Science ®Google Scholar
• Slob W. 2002. Dose-response modeling of continuous endpoints. Toxicol Sci. 66:298–312.
   PubMed Web of Science ®Google Scholar
• Slob W, Bakker MI, Biesebeek JD, Bokkers BG. 2014. Exploring the uncertainties in cancer risk assessment using the integrated probabilistic risk assessment (IPRA) approach. Risk Anal. 34:1401–1422.
   PubMed Web of Science ®Google Scholar
• Slob W, Setzer RW. 2014. Shape and steepness of toxicological dose-response relationships of continuous endpoints. Crit Rev Toxicol. 44:270–297.
   PubMed Web of Science ®Google Scholar
• Smith MT, Guyton KZ, Gibbons CF, Fritz JM, Portier CJ, Rusyn I, DeMarini DM, Caldwell JC, Kavlock RJ, Lambert PF, et al. 2016. Key characteristics of carcinogens as a basis for organizing data on mechanisms of carcinogenesis. Environ Health Perspect. 124:713–721.
   PubMed Web of Science ®Google Scholar
• Soeteman-Hernandez LG, Johnson GE, Slob W. 2016. Estimating the carcinogenic potency of chemicals from the in vivo micronucleus test. Mutagenesis. 31:347–358.
   PubMed Web of Science ®Google Scholar
• Thomas RS, Philbert MA, Auerbach SS, Wetmore BA, Devito MJ, Cote I, Rowlands JC, Whelan MP, Hays SM, Andersen ME, et al. 2013. Incorporating new technologies into toxicity testing and risk assessment: moving from 21st century vision to a data-driven framework. Toxicol Sci. 136:4–18.
   PubMed Web of Science ®Google Scholar
• US EPA. 1995. The use of the benchmark dose approach in health risk assessment. Washington (DC): EPA.
   Google Scholar
• van der Laan JW, Buitenhuis WH, Wagenaar L, Soffers AE, van Someren EP, Krul CA, Woutersen RA. 2016. Prediction of the carcinogenic potential of human pharmaceuticals using repeated dose toxicity data and their pharmacological properties. Front Med. 3:45.
   PubMed Web of Science ®Google Scholar
• van der Laan JW, Kasper P, Silva Lima B, Jones DR, Pasanen M. 2016. Critical analysis of carcinogenicity study outcomes. Relationship with pharmacological properties. Crit Rev Toxicol. 46:587–614.
   PubMed Web of Science ®Google Scholar
• van Leeuwen CJ, Vermeire TG. 2007. Risk assessment of chemicals: an introduction. Dordrecht, the Netherlands: Springer Science & Business Media.
   Google Scholar
• WHO. 2014. Guidance document on evaluating and expressing uncertainty in hazard characterization. Geneva, Switzerland: WHO.
   Google Scholar
• Williams GM. 2001. Mechanisms of chemical carcinogenesis and application to human cancer risk assessment. Toxicology. 166:3–10.
   PubMed Web of Science ®Google Scholar
• Williams GM. 2008. Application of mode-of-action considerations in human cancer risk assessment. Toxicol Lett. 180:75–80.
   PubMed Web of Science ®Google Scholar
• Wills JW, Long AS, Johnson GE, Bemis JC, Dertinger SD, Slob W, White PA. 2016. Empirical analysis of BMD metrics in genetic toxicology part II: in vivo potency comparisons to promote reductions in the use of experimental animals for genetic toxicity assessment. Mutagenesis. 31:265–275.
   PubMed Web of Science ®Google Scholar